idarubicin has been researched along with valproic acid in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (63.64) | 29.6817 |
| 2010's | 2 (18.18) | 24.3611 |
| 2020's | 2 (18.18) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bueso-Ramos, C; Garcia-Manero, G; Hoshino, K; Quintas-Cardama, A; Richon, VM; Sanchez-Gonzalez, B; Yang, H | 1 |
| Brossart, P; Brugger, W; Derigs, HG; Döhner, H; Döhner, K; Gaidzik, VI; Göttlicher, M; Götze, K; Greil, R; Heil, G; Held, G; Horst, HA; Kirchen, H; Köhne, CH; Koller, E; Kremers, S; Matzdorff, A; Nachbaur, D; Paschka, P; Raghavachar, A; Ringhoffer, M; Schlenk, RF; Tassara, M; Wattad, M; Wulf, G | 1 |
| Adès, L; Amé, S; Benramdane, R; Beyne-Rauzy, O; Bordessoule, D; Braun, T; Chermat, F; Chevret, S; Cheze, S; Cluzeau, T; de Botton, S; Dimicoli-Salazar, S; Duployez, N; Fenaux, P; Guerci-Bresler, A; Laribi, K; Marolleau, JP; Nimubona, S; Park, S; Peterlin, P; Preudhomme, C; Quesnel, B; Recher, C; Stamatoullas, A; Thepot, S; Toma, A; Vey, N; Wattel, E; Wickenhauser, S; Zerazhi, H | 1 |
| Seymour, JF; Wei, AH | 1 |
1 review(s) available for idarubicin and valproic acid
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 trial(s) available for idarubicin and valproic acid
| Article | Year |
|---|---|
Valproic acid in combination with all-trans retinoic acid and intensive therapy for acute myeloid leukemia in older patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Critical Care; Cytarabine; Disease-Free Survival; Drug Synergism; Enzyme Inhibitors; Female; Follow-Up Studies; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Nuclear Proteins; Nucleophosmin; Survival Rate; Tretinoin; Valproic Acid | 2014 |
A randomised phase II study of azacitidine (AZA) alone or with Lenalidomide (LEN), Valproic acid (VPA) or Idarubicin (IDA) in higher-Risk MDS or low blast AML: GFM's "pick a winner" trial, with the impact of somatic mutations.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Humans; Idarubicin; Lenalidomide; Leukemia, Myeloid, Acute; Mutation; Treatment Outcome; Valproic Acid | 2022 |
8 other study(ies) available for idarubicin and valproic acid
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Antileukemia activity of the combination of an anthracycline with a histone deacetylase inhibitor.
Topics: Acetylation; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Cell Survival; Cyclin-Dependent Kinase Inhibitor p21; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Enzyme Inhibitors; Gene Expression Regulation, Leukemic; Histone Deacetylase Inhibitors; Histone Deacetylases; Histones; HL-60 Cells; Humans; Hydroxamic Acids; Idarubicin; Leukemia; Protein Processing, Post-Translational; RNA, Messenger; Valproic Acid; Vorinostat | 2006 |
Enhancing our chances of picking a winner in higher-risk myelodysplastic syndromes.
Topics: Azacitidine; Clinical Trials, Phase II as Topic; Humans; Idarubicin; Lenalidomide; Myelodysplastic Syndromes; Randomized Controlled Trials as Topic; Valproic Acid | 2022 |